Protara Therapeutics (TARA) Consolidated Net Income (2013 - 2026)

Protara Therapeutics (TARA) has reported Consolidated Net Income for 14 consecutive years, with -$28.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 58.4% year-over-year to -$28.9 million; the TTM figure through Mar 2026 stood at -$88.8 million (down 52.32% YoY), while the FY2025 annual figure was -$148.1 million, down 25.13% from the prior year.
• Consolidated Net Income eased to -$28.9 million in Q1 2026 per TARA's latest filing, from -$19.5 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$9.1 million in Q3 2022 and bottomed at -$40.1 million in Q4 2022.
• Historically, Consolidated Net Income has averaged -$16.5 million across 5 years, with a median of -$13.4 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 225.29% — and 2023, when it soared 67.56%.
• Protara Therapeutics' Consolidated Net Income stood at -$40.1 million in 2022, then jumped by 67.56% to -$13.0 million in 2023, then increased by 12.45% to -$11.4 million in 2024, then tumbled by 71.29% to -$19.5 million in 2025, then slumped by 48.42% to -$28.9 million in 2026.
• Business Quant data shows TARA's Consolidated Net Income at -$28.9 million in Q1 2026, -$19.5 million in Q4 2025, and -$19.4 million in Q3 2025.